Suppr超能文献

单独使用甲硝唑或联合阿莫西林作为慢性牙周炎非手术治疗的辅助手段:一项为期 1 年的双盲、安慰剂对照、随机临床试验。

Metronidazole alone or with amoxicillin as adjuncts to non-surgical treatment of chronic periodontitis: a 1-year double-blinded, placebo-controlled, randomized clinical trial.

机构信息

Department of Periodontology, Dental Research Division, Guarulhos University, Guarulhos, São Paulo, Brazil.

出版信息

J Clin Periodontol. 2012 Dec;39(12):1149-58. doi: 10.1111/jcpe.12004. Epub 2012 Sep 27.

Abstract

AIM

To evaluate the effects of the adjunctive use of metronidazole (MTZ) or MTZ + amoxicillin (AMX) in the treatment of generalized chronic periodontitis (ChP). A secondary aim was to examine a possible added effect of chlorhexidine to these therapies.

METHODS

One hundred and eighteen subjects received scaling and root planing (SRP) only or with MTZ [400 mg/thrice a day (TID)] or MTZ+AMX (500 mg/TID) for 14 days. Half of the subjects in each group rinsed with 0.12% chlorhexidine twice a day (BID) for 2 months. Subjects were clinically monitored at baseline, 3, 6 and 12-months post-therapy.

RESULTS

The two antibiotic groups showed lower mean number of sites with probing depth (PD) ≥5 mm and fewer subjects exhibiting ≥9 of these sites at 1-year post-treatment. Logistic regression analysis showed that antibiotics were the only significant predictors of subjects presenting ≤4 sites with PD ≥5 mm at 1 year (MTZ+AMX: OR, 13.33; 95%CI, 3.75-47.39/p = 0.0000; MTZ: OR, 7.26; 95%CI, 2.26-23.30/p = 0.0004). The frequency of adverse events did not differ between the two antibiotic treatments (p > 0.05). The chlorhexidine subgroups showed a trend (p > 0.05) to present fewer residual sites ≥5 mm compared with the placebo subgroups at 1 year.

CONCLUSION

Treatment of generalized ChP is significantly improved by the adjunctive use of MTZ+AMX and MTZ.

摘要

目的

评估甲硝唑(MTZ)或 MTZ+阿莫西林(AMX)辅助治疗广泛性慢性牙周炎(ChP)的效果。次要目的是研究洗必泰对这些治疗方法是否有额外作用。

方法

118 名受试者接受了龈下刮治和根面平整(SRP)治疗,或在 SRP 基础上联合 MTZ[400mg/每天三次(TID)]或 MTZ+AMX(500mg/TID)治疗 14 天。每组的一半受试者使用 0.12%洗必泰每天两次(BID)漱口,持续 2 个月。受试者在基线、治疗后 3、6 和 12 个月时进行临床监测。

结果

两组抗生素组在治疗后 1 年时,平均探诊深度(PD)≥5mm的位点数量较低,且≥9 个位点的受试者比例也较少。Logistic 回归分析显示,抗生素是治疗后 1 年时 PD≥5mm的位点数≤4 的唯一显著预测因子(MTZ+AMX:比值比,13.33;95%置信区间,3.75-47.39/p=0.0000;MTZ:比值比,7.26;95%置信区间,2.26-23.30/p=0.0004)。两种抗生素治疗的不良反应发生率无差异(p>0.05)。洗必泰亚组与安慰剂亚组相比,在治疗后 1 年时,PD≥5mm的残留位点数量呈减少趋势(p>0.05)。

结论

MTZ+AMX 和 MTZ 的辅助治疗可显著改善广泛性 ChP 的治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验